Absence of NPM1 promoter hypermethylation in human myelodysplastic syndrome

Journal of Clinical Pathology

Volumn 63, Issue 11, 2010, Pages 1008-1011

  Cheng, Yuen Yee ^a,b   Chau, David ^a   Chan, Thomas ^a   Gill, Harinder ^a   Liang, Raymond ^a   Kwong, Yok Lam ^a   Tse, Eric ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; MESSENGER RNA; NUCLEOPHOSMIN;

ADULT; AGED; ARTICLE; BLOOD; BONE MARROW; BONE MARROW BIOPSY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DNA EXTRACTION; DNA METHYLATION; DNA SEQUENCE; FEMALE; GENE EXPRESSION; GENE MUTATION; GENE REPRESSION; GENETIC TRANSCRIPTION; HUMAN; MALE; MYELODYSPLASTIC SYNDROME; PATHOGENESIS; PATHOGENICITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; DNA METHYLATION; FEMALE; GENE EXPRESSION; GENETIC PREDISPOSITION TO DISEASE; HAPLOINSUFFICIENCY; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NUCLEAR PROTEINS; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; YOUNG ADULT;

EID: 78149359076     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jcp.2010.080465     Document Type: Article

References (11)

1. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042-54.
2. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009;10:223-32.
3. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006;106:1794-803.
4. Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005;352:254-66.
5. Grisendi S, Bernardi R, Rossi M, et al. Role of nucleophosmin in embryonic development and tumorigenesis. Nature 2005;437:147-53.
6. Ishikawa Y, Xu J, Sakashita G, et al. Abnormal cytoplasmic dyslocalisation and/or reduction of nucleophosmin protein level rarely occurs in myelodysplastic syndromes. Leuk Lymphoma 2008;49:2359-64.
7. Oki Y, Jelinek J, Beran M, et al. Mutations and promoter methylation status of NPM1 in myeloproliferative disorders. Haematologica 2006;91:1147-8. (Pubitemid 44204790)
8. Uhlmann K, Brinckmann A, Toliat MR, et al. Evaluation of a potential epigenetic biomarker by quantitative methyl-single nucleotide polymorphism analysis. Electrophoresis 2002;23:4072-9.
9. Colella S, Shen L, Baggerly KA, et al. Sensitive and quantitative universal Pyrosequencing methylation analysis of CpG sites. Biotechniques 2003;35:146-50. (Pubitemid 36828724)
10. Tost J, Dunker J, Gut IG. Analysis and quantification of multiple methylation variable positions in CpG islands by Pyrosequencing. Biotechniques 2003;35:152-6.
11. Suzuki T, Kiyoi H, Ozeki K, et al. Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. Blood 2005;106:2854-61.